RxDoctor Payments Data

Amanda Sollars, MD

Family Medicine · Columbia, MDNPI 1619210960

Payments from drug & device makers

$866in general payments, 2019–2025

Across 37 payments — averaging $23.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Globus Medical$165
  • Astellas Pharma US Inc$150
  • Novo Nordisk$105
  • GSK$105
  • Nevro Corp.$103
  • AstraZeneca$86
  • plus $152 from 6 others

What the payments were for

  • Food & beverage$83897%
  • Education$283%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$866 in reported general payments places this provider in the 65th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$75,473
Medicare patients
213
Services billed
834

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban45$62,983
OzempicSemaglutide43$46,564
MounjaroTirzepatide26$32,179
FarxigaDapagliflozin Propanediol27$27,585
TrulicityDulaglutide20$23,223
JanuviaSitagliptin Phosphate13$21,243
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$18,505
JardianceEmpagliflozin15$16,261
LinzessLinaclotide14$11,076
SymbicortBudesonide/Formoterol Fumarate41$10,955
XareltoRivaroxaban11$9,233
Tresiba Flextouch U-100Insulin Degludec18$7,938
VascepaIcosapent Ethyl12$4,537
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$3,918
Humalog Kwikpen U-100Insulin Lispro16$3,628

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12$62,98345 claims
Lilly USA, LLCMounjaro, Trulicity, Olanzapine$12$58,52576 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$86$57,04592 claims
Novo NordiskOzempic$105$46,56443 claims
AbbVieLinzess$16$11,07614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Columbia

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →